Gamida Cell announced updated results from a Phase 1 clinical study of GDA-201, an investigational, natural killer cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, or NHL, and multiple myeloma, or MM, at the 61st Annual Meeting of the American Society of Hematology, ASH, which is being held December 7-10 in Orlando, Florida. Data from 22 patients in the ongoing study showed GDA-201 in combination with monoclonal antibodies was generally well tolerated and demonstrated early evidence of clinical activity in heavily pre-treated patients, including five complete responses observed among nine patients with NHL. Gamida Cell plans to initiate a Phase 1/2 multi-dose, multi-center study of GDA-201 in patients with NHL in 2020.